UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000006815
Receipt No. R000008048
Scientific Title Outcome study of Lanthanum Carbonate compared with Calcium carbonate on cardiovascular mortality and morbidity in patients with chronic kidney disease on hemodialysis: Landmark Study
Date of disclosure of the study information 2011/12/01
Last modified on 2020/11/27 (Ver. 10)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Outcome study of Lanthanum Carbonate compared with Calcium carbonate on cardiovascular mortality and morbidity in patients with chronic kidney disease on hemodialysis: Landmark Study
Acronym Outcome study of Lanthanum Carbonate compared with Calcium carbonate in hemodialysis patients: Landmark Study
Scientific Title Outcome study of Lanthanum Carbonate compared with Calcium carbonate on cardiovascular mortality and morbidity in patients with chronic kidney disease on hemodialysis: Landmark Study
Scientific Title:Acronym Outcome study of Lanthanum Carbonate compared with Calcium carbonate in hemodialysis patients: Landmark Study
Region
Japan

Condition
Condition Hemodialysis patients with hyperphosphatemia
Classification by specialty
Nephrology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To demonstrate decrease in cardiovascular mortality and morbidity in Japanese hemodialysis patients treated with Lanthanum Carbonate compared with those with Calcium Carbonate
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Phase III

Assessment
Primary outcomes Cardiovascular event free survival time
Following diseases were recognized;
1) death due to cardiovascular diseases including sudden cardiac death
2) nonfatal myocardial infarction
3) nonfatal cerebral stroke including transient ischemic attack, TIA
4) unstable angina
5) hospitalization for heart failure
6) hospitalization for ventricular arrhythmia
Key secondary outcomes - overall survival
- secondary hyperparathyroidism free survival
- hip fracture free survival
- quality of life questionnaire (KDQOL-SF, v1.3)
- bone mineral density (DEXA)

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -but assessor(s) are blinded
Control Active
Stratification YES
Dynamic allocation
Institution consideration Institution is considered as adjustment factor in dynamic allocation.
Blocking NO
Concealment Central registration

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Lanthanum carbonate treatment (Patients will be followed for three years after the last patient is enrolled )
Interventions/Control_2 Calcium carbonate treatment (Patients will be followed for three years after the last patient is enrolled )
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria - hemodialysis patients with hyperphosphatemia who require phosphate binders
- hemodialysis for more than 3 months
- patients who have at lease one calcification risk factor (elderly > 65 years, postmenopausal woman, type 2 diabetes mellitus)
- intact-PTH < or =240 pg/mL
- life expectancy > 1 year
- with written informed consent
Key exclusion criteria - contraindications to Ca carbonate and La carbonate
- swallowing disorders
- severe GI disorders
- history of obstructed bowels
- history of IHD/stroke within 6 months
- NYHA classification III-IV
- severe liver dysfunction, AST or ALT greater than 3 times the upper limit of institution
- require treatment of arrthythmia
- severe malnutrition
- malignancy of any type within the last 5 years
- peritoneal dialysis patients
- pregnant or possibly pregnant women or women on lactation and plan to get pregnant within study term
- ineligible patients according to the investigator's judgment
Target sample size 3000

Research contact person
Name of lead principal investigator
1st name Tadao
Middle name
Last name Akizawa
Organization Showa University
Division name Division of Nephrology, Department of Medicine
Zip code 1428555
Address 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan
TEL +81-3-3784-8000
Email akizawa@med.showa-u.ac.jp

Public contact
Name of contact person
1st name Hiroaki
Middle name
Last name Ogata
Organization Showa University Northern Yokohama Hospital
Division name Department of Internal Medicine
Zip code 2248503
Address 35-1 Chigasakichuo, Tsuzuki, Yokohama, Kanagawa, Japan
TEL +81-45-949-7000
Homepage URL
Email ogatah@med.showa-u.ac.jp

Sponsor
Institute Landmark Study Group
Institute
Department

Funding Source
Organization Bayer Yakuhin, Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor Foundation for Biomedical Research and Innovation at Kobe
Name of secondary funder(s)

IRB Contact (For public release)
Organization Showa University Clinical Trials Review Committee
Address Hatanodai 1-5-8, Shinagawa, Tokyo, Japan
Tel +81-3-3784-8000
Email ctsc.admin@ofc.showa-u.ac.jp

Secondary IDs
Secondary IDs YES
Study ID_1 NCT01578200
Org. issuing International ID_1 ClinicalTrials.gov
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2011 Year 12 Month 01 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications
Number of participants that the trial has enrolled 2347
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2011 Year 10 Month 17 Day
Date of IRB
2011 Year 10 Month 18 Day
Anticipated trial start date
2011 Year 11 Month 01 Day
Last follow-up date
2018 Year 06 Month 26 Day
Date of closure to data entry
2018 Year 11 Month 02 Day
Date trial data considered complete
2018 Year 11 Month 02 Day
Date analysis concluded
2019 Year 03 Month 25 Day

Other
Other related information

Management information
Registered date
2011 Year 12 Month 01 Day
Last modified on
2020 Year 11 Month 27 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008048